DK1761273T3 - Behandling af ikke-alkoholisk steatotisk hepatitis (NASH) - Google Patents

Behandling af ikke-alkoholisk steatotisk hepatitis (NASH)

Info

Publication number
DK1761273T3
DK1761273T3 DK05753069T DK05753069T DK1761273T3 DK 1761273 T3 DK1761273 T3 DK 1761273T3 DK 05753069 T DK05753069 T DK 05753069T DK 05753069 T DK05753069 T DK 05753069T DK 1761273 T3 DK1761273 T3 DK 1761273T3
Authority
DK
Denmark
Prior art keywords
nash
treatment
lpl
therapeutic
steatotic hepatitis
Prior art date
Application number
DK05753069T
Other languages
English (en)
Inventor
Deventer Sander Jan Hendri Van
Original Assignee
Amsterdam Molecular Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amsterdam Molecular Therapeutics Bv filed Critical Amsterdam Molecular Therapeutics Bv
Application granted granted Critical
Publication of DK1761273T3 publication Critical patent/DK1761273T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034Lipoprotein lipase (3.1.1.34)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK05753069T 2004-06-21 2005-06-20 Behandling af ikke-alkoholisk steatotisk hepatitis (NASH) DK1761273T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58090304P 2004-06-21 2004-06-21
PCT/NL2005/000446 WO2005123117A1 (en) 2004-06-21 2005-06-20 Treatment of non alcoholic steatotic hepatitis (nash)

Publications (1)

Publication Number Publication Date
DK1761273T3 true DK1761273T3 (da) 2008-08-04

Family

ID=34970452

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05753069T DK1761273T3 (da) 2004-06-21 2005-06-20 Behandling af ikke-alkoholisk steatotisk hepatitis (NASH)

Country Status (16)

Country Link
US (2) US20080280823A1 (da)
EP (1) EP1761273B1 (da)
JP (1) JP2008503569A (da)
KR (1) KR20070057712A (da)
CN (1) CN1972709A (da)
AT (1) ATE395073T1 (da)
AU (1) AU2005253897B2 (da)
CA (1) CA2568643A1 (da)
CY (1) CY1108552T1 (da)
DE (1) DE602005006809D1 (da)
DK (1) DK1761273T3 (da)
ES (1) ES2306163T3 (da)
PL (1) PL1761273T3 (da)
PT (1) PT1761273E (da)
SI (1) SI1761273T1 (da)
WO (1) WO2005123117A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056596A1 (en) 2000-02-04 2001-08-09 Children's Hospital Research Foundation Use of lysosomal acid lipase for treating atherosclerosis and related diseases
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
WO2010134806A1 (en) * 2009-05-18 2010-11-25 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Use of lipoprotein lipase (lpl) in therapy
CN102628060A (zh) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 一种低脂奶的生产方法
MA41035A (fr) * 2014-08-19 2017-08-15 Shire Human Genetic Therapies Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039880D1 (en) * 1999-06-24 2008-09-25 Amsterdam Molecular Therapeutics Bv Therapie mit lipoproteinlipase (lpl) variant
FR2795832B1 (fr) * 1999-06-30 2004-06-18 Plastic Omnium Valeo Interiors Dispositif de commande d'actionneur notamment pour vehicule
ATE438414T1 (de) * 2000-06-01 2009-08-15 Univ North Carolina Verfahren und zusammensetzungen zur kontrollierter abgabe von rekombinant parvovirus vektoren

Also Published As

Publication number Publication date
US20110081332A1 (en) 2011-04-07
KR20070057712A (ko) 2007-06-07
ATE395073T1 (de) 2008-05-15
CA2568643A1 (en) 2005-12-29
SI1761273T1 (sl) 2008-10-31
ES2306163T3 (es) 2008-11-01
DE602005006809D1 (de) 2008-06-26
AU2005253897A1 (en) 2005-12-29
AU2005253897B2 (en) 2011-09-01
PT1761273E (pt) 2008-10-28
WO2005123117A1 (en) 2005-12-29
CN1972709A (zh) 2007-05-30
US20080280823A1 (en) 2008-11-13
EP1761273A1 (en) 2007-03-14
EP1761273B1 (en) 2008-05-14
CY1108552T1 (el) 2014-04-09
PL1761273T3 (pl) 2008-10-31
JP2008503569A (ja) 2008-02-07

Similar Documents

Publication Publication Date Title
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
NO20054769L (no) Substituerte fenylalkansyrer
DK1599575T3 (da) Fremgangsmåder til anvendelse af adipøst vævs-afledte celler i behandlingen af kardiovaskulære tilstande
NO20054958L (no) Substitulerte aminokarboksylsyrer
EA200501710A1 (ru) Замещённые карбоновые кислоты
DE602006012513D1 (de) Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
EA200900298A1 (ru) Ингибиторы вируса гепатита с
NO20064059L (no) Albumin fusjonsproteiner
NO20071240L (no) Terapeutiske anvendelser av RTP801 inhibitorer
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
ATE447574T1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
WO2007030375A3 (en) Lysosomal acid lipase therapy for nafld and related diseases
SG179410A1 (en) Therapeutic uses of inhibitors of rtp801
MX2007004841A (es) Triazoles utiles como inhibidores de proteinas cinasas.
DE60229041D1 (de) Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
NO20082510L (no) En fremgangsmate for konsentrasjon av et polypeptid
DK1761273T3 (da) Behandling af ikke-alkoholisk steatotisk hepatitis (NASH)
EA201001749A1 (ru) Способ лечения недифференцированного артрита
ATE536745T1 (de) Zusammensetzung mit arazym zur prävention und behandlung von krebs
ATE546155T1 (de) Verfahren zur stabilisierung eines kryopräzipitats von plasmatischen proteinen für eine wärmebehandlung zur viralen inaktivierung
WO2009138146A3 (de) Neue therapeutika für die hepatitis-therapie
ATE365807T1 (de) Hepatitis b virus vektoren für gentherapie
DE602004012404D1 (de) Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna)